The Official Stance On Testosterone Therapy Changed — What It Means For You
Key takeaways
- Author: Sela Breen June 18, 2026Assistant Health Editor By Sela Breen Assistant Health Editor Sela Breen is the Assistant Health Editor at mindbodygreen.
- Department of Health and Human Services (HHS) announced that it is requesting updates to testosterone replacement therapy (TRT) prescribing information (labeling).
- HHS is now requesting that this limitation be removed.
Why this matters: practical guidance grounded in recent research or expert insight.
Author: Sela Breen June 18, 2026Assistant Health Editor By Sela Breen Assistant Health Editor Sela Breen is the Assistant Health Editor at mindbodygreen. She is a graduate of the Medill School of Journalism at Northwestern University, where she studied journalism, international studies, and theatre.Image by Sean Locke / Stocksy June 18, 2026Most men assume that if their testosterone is low, they can get treatment. But since 2015, FDA labeling has included cautionary language noting that the safety and effectiveness of testosterone therapy in age-related low testosterone had not been established.
But on June 18, the U.S. Department of Health and Human Services (HHS) announced that it is requesting updates to testosterone replacement therapy (TRT) prescribing information (labeling). If finalized, the changes would remove that statement and revise two other major safety warnings.
Since 2015, testosterone replacement therapy product labeling has included a limitation stating that safety and effectiveness had not been established in men with age-related hypogonadism, a condition involving low testosterone levels without a known underlying cause. HHS is now requesting that this limitation be removed.